Hybrid tandem and ovoids brachytherapy in locally advanced cervical cancer: impact of dose and tumor volume metrics on outcomes.

PURPOSE

To report the impact of dose and tumor volume metrics at brachytherapy on outcomes for locally advanced cervical cancer treated with tandem and ovoids intracavitary/interstitial brachytherapy.

MATERIAL AND METHODS

FIGO stage IB1-IIIB locally advanced cervical cancer treated with intracavitary/interstitial brachytherapy via a tandem and ovoids hybrid applicator were analyzed. Median high-risk clinical target volume (HR-CTV), rate of tumor volume reduction, EQD D, organ at risk doses, and outcomes were recorded. Univariable and multivariable Cox regression was applied for survival analysis, and logistic regression was used for toxicity analysis.

RESULTS

Seventy-one patients were identified. Median follow-up was 24.9 months, with a 2-year local control of 83.6%, loco-regional control of 72.0%, and overall survival of 88.6%. Median HR-CTV D was 87.4 Gy (IQR = 85.7-90.2). Median HR-CTV D > 90 Gy showed a trend toward improved local control (LC) ( = 0.19). Median HR-CTV was 37.9 cm, and median V was 86.5%. A median HR-CTV of ≥ 40 cm demonstrated worse loco-regional control (LRC) ( = 0.018) and progression-free survival ( = 0.021). Two-year LC and LRC for stage IIB patients with a median HR-CTV < 40 cm were significantly improved as compared to ≥ 40 cm at 100% and 71.8%, respectively ( = 0.019) and 100% and 56.5%, respectively ( = 0.001). However, this trend was not statistically significant for stage IIIB patients. Higher percent per day reduction in HR-CTV during brachytherapy showed improved LRC ( = 0.045). Four percent of patients experienced acute grade 3 genitourinary toxicity, 1% late grade 3 genitourinary and 1% late grade 3 gastrointestinal toxicity.

CONCLUSIONS

Tandem and ovoids intracavitary/interstitial brachytherapy provides satisfactory outcomes with modest toxicity. Higher HR-CTV D coverage demonstrated a trend toward improved tumor control. Tumor volume based on median HR-CTV ≥ 40 cm at brachytherapy was prognostic for poor outcomes, even within initial FIGO stage groups warranting caution.